Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma
Crossref DOI link: https://doi.org/10.1007/s12032-015-0675-y
Published Online: 2015-08-13
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Guo, Mengzhou
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Qian
Feng, Yi
Li, Wei
Zhuang, RongYuan
Liu, Tianshu
Text and Data Mining valid from 2015-08-13